Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group.
Christoph ThomssenMartina VetterEva Johanna KantelhardtChristoph MeisnerMarcus SchmidtPierre M MartinFlorian ClatotDoris AugustinVolker HanfDaniela PaepkeWolfgang MeinerzGerald HoffmannWolfgang WiestFred C G J SweepManfred SchmittFritz JänickeSibylle LoiblGunter von MinckwitzNadia Harbecknull nullPublished in: Cancers (2023)
With adequate adjuvant chemotherapy, even high-risk node-negative breast cancer patients have an excellent prognosis. Docetaxel did not further reduce the rate of early recurrences and led to significantly more treatment discontinuations.